158 related articles for article (PubMed ID: 16698281)
1. Epigenetic silencing of 14-3-3sigma in cancer.
Lodygin D; Hermeking H
Semin Cancer Biol; 2006 Jun; 16(3):214-24. PubMed ID: 16698281
[TBL] [Abstract][Full Text] [Related]
2. The role of epigenetic inactivation of 14-3-3sigma in human cancer.
Lodygin D; Hermeking H
Cell Res; 2005 Apr; 15(4):237-46. PubMed ID: 15857578
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
Lodygin D; Diebold J; Hermeking H
Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3sigma is down-regulated in human prostate cancer.
Urano T; Takahashi S; Suzuki T; Fujimura T; Fujita M; Kumagai J; Horie-Inoue K; Sasano H; Kitamura T; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2004 Jul; 319(3):795-800. PubMed ID: 15184053
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Horie-Inoue K; Inoue S
Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214
[TBL] [Abstract][Full Text] [Related]
6. 14-3-3 proteins--an update.
Mhawech P
Cell Res; 2005 Apr; 15(4):228-36. PubMed ID: 15857577
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of 14-3-3sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front.
Ide M; Nakajima T; Asao T; Kuwano H
Cancer Lett; 2004 Apr; 207(2):241-9. PubMed ID: 15072834
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of 14-3-3sigma in budding colorectal cancer cells modulates cell migration in the presence of tenascin-C.
Ide M; Saito K; Tsutsumi S; Tsuboi K; Yamaguchi S; Asao T; Kuwano H; Nakajima T
Oncol Rep; 2007 Dec; 18(6):1451-6. PubMed ID: 17982629
[TBL] [Abstract][Full Text] [Related]
9. Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma.
Lodygin D; Yazdi AS; Sander CA; Herzinger T; Hermeking H
Oncogene; 2003 Aug; 22(35):5519-24. PubMed ID: 12934112
[TBL] [Abstract][Full Text] [Related]
10. Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia.
Gasco M; Sullivan A; Repellin C; Brooks L; Farrell PJ; Tidy JA; Dunne B; Gusterson B; Evans DJ; Crook T
Oncogene; 2002 Mar; 21(12):1876-81. PubMed ID: 11896620
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance.
Reibenwein J; Pils D; Horak P; Tomicek B; Goldner G; Worel N; Elandt K; Krainer M
Prostate; 2007 Mar; 67(4):427-32. PubMed ID: 17192910
[TBL] [Abstract][Full Text] [Related]
12. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
13. [14-3-3sigma (stratifin), a potential tumor suppressor frequently inactivated by methylation in cancer of the breast].
Jeanteur P
Bull Cancer; 2000 Jul; 87(7-8):525. PubMed ID: 10969206
[No Abstract] [Full Text] [Related]
14. Targeted proteomic analysis of 14-3-3sigma in nasopharyngeal carcinoma.
Huang WG; Cheng AL; Chen ZC; Peng F; Zhang PF; Li MY; Li F; Li JL; Li C; Yi H; Li XH; Yi B; Xiao ZQ
Int J Biochem Cell Biol; 2010 Jan; 42(1):137-47. PubMed ID: 19828132
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic applications of epigenetics.
Miyamoto K; Ushijima T
Jpn J Clin Oncol; 2005 Jun; 35(6):293-301. PubMed ID: 15930038
[TBL] [Abstract][Full Text] [Related]
16. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer.
Hu XT; Zhang FB; Fan YC; Shu XS; Wong AH; Zhou W; Shi QL; Tang HM; Fu L; Guan XY; Rha SY; Tao Q; He C
Oncogene; 2009 Jul; 28(26):2466-75. PubMed ID: 19448674
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3sigma-dependent resistance to cisplatin.
Han Z; Dimas K; Tian X; Wang Y; Hemmi H; Yamada K; Kato N; Pantazis P; Ramanujam RJ; Anant S; Wyche JH; Houchen CW
Anticancer Res; 2009 Jun; 29(6):2009-14. PubMed ID: 19528459
[TBL] [Abstract][Full Text] [Related]
18. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.
Tanaka K; Imoto I; Inoue J; Kozaki K; Tsuda H; Shimada Y; Aiko S; Yoshizumi Y; Iwai T; Kawano T; Inazawa J
Oncogene; 2007 Sep; 26(44):6456-68. PubMed ID: 17438526
[TBL] [Abstract][Full Text] [Related]
19. Human astrocytes express 14-3-3 sigma in response to oxidative and DNA-damaging stresses.
Satoh J; Tabunoki H; Nanri Y; Arima K; Yamamura T
Neurosci Res; 2006 Sep; 56(1):61-72. PubMed ID: 16797759
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]